Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of PCV20 in Chronic Respiratory Disease Patients
jRCT1031240601Active, not recruiting
- Sponsor
- not applicable
- Start
- Jan 2025
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of Prevnar 20 in pneumococcal disease, sponsored by not applicable. Primary endpoint: Geometric mean antibody titer at 1 month. Started Jan 2025; status: active, not recruiting.
02
Drugs
Prevnar 20
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on jRCT1031240601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031240601.